BioMarin Pharmaceutical Inc (BMRN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

105 DIGITAL DRIVE NOVATO, CA 94949

Biomarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of three approved products and multiple investigational product candidates. Approved products include Aldurazyme, Naglazyme, and Orapred.

Data based on most recent fiscal year report
Market Cap13.597 Billion Shares Outstanding175.62 Million Avg Volume1.975 Million
1-Yr BETA vs S&P TR Current Ratio2.7 Quick Ratio2.12
View SEC Filings from BMRN instead.
Q2 2019 All Institutions Hedge Funds 1
To trade BMRN now:
Filers who had this stock in their top 10: 9 7 (0.72%)
13F Filers holding this stock: 461 67 (6.92%)
Aggregate 13F shares on 06/30/2019: 175.895 Million 24.019 Million
Aggregate 13F shares on 03/31/2019: 176.655 Million 23.074 Million
Percent change: -0.43% 4.10%
Funds creating new positions: 54 14
Funds Adding to an existing position: 163 22
Funds closing out their position: 54 13
Funds reducing their position: 171 23
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding BMRN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

3.8 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

4.8 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KAKKIS EMIL D PRESIDENT & CEO

  • Officer
  • Director
3,035,655 2019-10-14 0

FUCHS HENRY J

  • Director
7,833 2019-10-01 5

BIENAIME JEAN JACQUES

  • Director
7,274 2019-09-30 35

AJER JEFFREY ROBERT

  • Director
22,375 2019-09-30 9

HOMBACH ROBERT J.

  • Director
0 2019-09-30 1

KLEIN JOSEPH III

  • Director
0 2019-09-20 0

LAWLIS V BRYAN

  • Director
23,590 2019-09-17 5

ASELAGE STEVE

  • Director
6,672 2019-09-01 0

GREY MICHAEL G

1,798 2019-08-12 1

HERON ELAINE J

  • Director
47,668 2019-08-07 2

BATE KENNETH

  • Director
0 2019-07-18 0

ANDERSON ELIZABETH M

  • Director
4,490 2019-07-09 2

PYOTT DAVID E I

  • Director
0 2019-07-01 1

DERE WILLARD H

  • Director
0 2019-06-13 1

FALBERG KATHRYN E

  • Director
162,610 2019-06-13 0

COOPER JEFFREY H

  • Director
0 2019-06-11 0

MEIER RICHARD A

  • Director
80,040 2019-06-11 2

BAFFI ROBERT PRESIDENT, GLOBAL MFG/TECH OPS

  • Officer
179,300 2019-06-05 5

LEWIS ALAN

  • Director
25,590 2019-06-04 1

SLAMON DENNIS

  • Director
18,615 2019-06-04 1

YOUNG WILLIAM D

  • Director
9,311 2019-06-01 0

DAVIS GEORGE ERIC EVP, GENERAL COUNSEL

  • Officer
71,899 2019-04-30 5

MUELLER BRIAN SVP, FINANCE AND CAO

  • Officer
13,959 2019-04-30 5

SPIEGELMAN DANIEL K EVP, CHIEF FINANCIAL OFFICER

  • Officer
47,686 2019-04-30 7

LAPALME PIERRE

  • Director
19,083 2018-03-05 0

WOOD MARK VP, HUMAN RESOURCES

  • Officer
20,277 2013-05-22 0

SWIEDLER STUART J SVP, CLINICAL AFFAIRS

  • Officer
No longer subject to file 2008-07-07 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER

2019-09-27 M 1,000 d 138,000 508,861.00 direct

BIENAIME JEAN JACQUES - Director - Officer CHIEF EXECUTIVE OFFICER

2019-09-27 M 1,000 $21.51 a 327,520 508,861.00 direct

LAWLIS V BRYAN - Director

2019-09-17 M 3,750 $21.51 a 27,340 23,590.00 direct

LAWLIS V BRYAN - Director

2019-09-17 M 3,750 d 7,500 23,590.00 direct

LAWLIS V BRYAN - Director

2019-09-17 S 3,750 $74.47 d 23,590 23,590.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments